home / stock / skye / skye news

SKYE News and Press, Skye Bioscience Inc Com From 01/27/23

Stock Information
Company Name: Skye Bioscience Inc Com
Stock Symbol: SKYE
Market: NASDAQ
Website: skyebioscience.com
Menu
SKYE SKYE Quote SKYE Short SKYE News SKYE Articles SKYE Message Board
Get SKYE Alerts

News, Short Squeeze, Breakout and More Instantly...
SKYE - Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion

San Diego, California--(Newsfile Corp. - January 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that its Phase 2 clinical trial protocol has received study l...
SKYE - Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.

Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I clinical study for Skye Bioscience, Inc.’s (SKYE: OTCQB) proprietary, synthetic cannabinoid ...

SKYE - Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE

Phase 2 clinical trial planned to start in H1 2023 San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced t...

SKYE - Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of SBI-100 Ophthalmic Em...
SKYE - Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer

San Diego, California--(Newsfile Corp. - December 13, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has hired Chris Twitty, PhD, as the Company's first chief scientific officer (CSO). With...

SKYE - Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference

San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced today that it will present a corporate overview at the R...

SKYE - Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA

San Diego, California--(Newsfile Corp. - November 17, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has submitted an Investigational New Drug application ("IND") to the U.S. Food and Dr...
SKYE - Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100

- Recruitment for cohort 1 has begun - Clinical trial material manufactured and shipped to Australia San Diego, California--(Newsfile Corp. - November 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic c...

SKYE - EMERALD HEALTH SCIENCES INC. - EARLY WARNING NEWS RELEASE

EMERALD HEALTH SCIENCES INC. - EARLY WARNING NEWS RELEASE Canada NewsWire VANCOUVER, BC , Nov. 11, 2022 /CNW/ - Emerald Health Sciences Inc. (" Sciences ") announces that on November 10, 2022 , it beneficially owns and controls the following secur...

SKYE - Skye Bioscience Closes Acquisition of Emerald Health Therapeutics

San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has concluded the merger transaction with Emerald Health Therapeut...
Previous 10 Next 10